BEAM THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.26 USD | -5.68% |
|
-8.08% | -21.90% |
| May. 07 | Beam Therapeutics Shares Fall After Q1 Revenue Misses Estimates | MT |
| May. 07 | Beam Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Presenter SpeechHuidong Wang (Analysts)Thank you. Good morning, everyone. My name is Gena Wang...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
21.26
USD
Average target price
48.38
USD
Spread / Average Target
+127.59%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -21.90% | 1.68B | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- BEAM Stock
- News Beam Therapeutics Inc.
- Transcript : Beam Therapeutics Inc. Presents at Barclays Gene Editing & Gene Therapy Summit 2023, May-24-2023 11
